Blood serum atherogenicity and coronary artery calcification

Igor A. Sobenin, Veronica A. Myasoedova, Elena V. Anisimova, Xenia N. Pavlova, Stefan Möhlenkamp, Axel Schmermund, Rainer Seibel, Sina Berenbein, Nils Lehmann, Susanne Moebus, Karl Heinz Jöckel, Alexander N. Orekhov, Raimund Erbel

Research output: Contribution to journalArticle

Abstract

The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-media thickness progression. The present study was undertaken to test the hypothesis that blood serum atherogenicity and its changes in dynamics may be associated with accumulation of coronary calcium in subclinical atherosclerosis. It was performed in 782 CHD-free participants of The Heinz Nixdorf RECALL (Risk Factors, Evaluation of Coronary Calcium and Lifestyle) Study, in whom blood samples have been taken at the baseline and at the end of 5-year follow-up. Opposite to the previous findings, the changes in serum atherogenicity did not correlate neither with the extent of coronary artery calcification, nor with the changes in Agatston CAC score. There was a moderate but significant rise in serum atherogenicity after 5-year followup period, and the same dynamics was observed for Agatston CAC score, but not for convenient lipid-related risk factors. The absence of association of the changes in serum atherogenicity with the changes in Agatston CAC score, along with previous findings, provides a point of view that serum-induced intracellular cholesterol accumulation is not related to the processes of calcium deposition in arterial wall, since the last one reflects the progression of already existing subclinical atherosclerotic lesions.

Original languageEnglish
Pages (from-to)5884-5888
Number of pages5
JournalCurrent Pharmaceutical Design
Volume20
Issue number37
Publication statusPublished - Mar 1 2014

Fingerprint

Coronary Vessels
Serum
Calcium
Lipids
Carotid Intima-Media Thickness
Aptitude
Life Style
Cultured Cells
Atherosclerosis
Cholesterol
Prospective Studies

Keywords

  • Biomarkers
  • Coronary artery calcification
  • Intracellular cholesterol accumulation
  • Lipids
  • Serum atherogenicity
  • Subclinical atherosclerosis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Sobenin, I. A., Myasoedova, V. A., Anisimova, E. V., Pavlova, X. N., Möhlenkamp, S., Schmermund, A., ... Erbel, R. (2014). Blood serum atherogenicity and coronary artery calcification. Current Pharmaceutical Design, 20(37), 5884-5888.

Blood serum atherogenicity and coronary artery calcification. / Sobenin, Igor A.; Myasoedova, Veronica A.; Anisimova, Elena V.; Pavlova, Xenia N.; Möhlenkamp, Stefan; Schmermund, Axel; Seibel, Rainer; Berenbein, Sina; Lehmann, Nils; Moebus, Susanne; Jöckel, Karl Heinz; Orekhov, Alexander N.; Erbel, Raimund.

In: Current Pharmaceutical Design, Vol. 20, No. 37, 01.03.2014, p. 5884-5888.

Research output: Contribution to journalArticle

Sobenin, IA, Myasoedova, VA, Anisimova, EV, Pavlova, XN, Möhlenkamp, S, Schmermund, A, Seibel, R, Berenbein, S, Lehmann, N, Moebus, S, Jöckel, KH, Orekhov, AN & Erbel, R 2014, 'Blood serum atherogenicity and coronary artery calcification', Current Pharmaceutical Design, vol. 20, no. 37, pp. 5884-5888.
Sobenin IA, Myasoedova VA, Anisimova EV, Pavlova XN, Möhlenkamp S, Schmermund A et al. Blood serum atherogenicity and coronary artery calcification. Current Pharmaceutical Design. 2014 Mar 1;20(37):5884-5888.
Sobenin, Igor A. ; Myasoedova, Veronica A. ; Anisimova, Elena V. ; Pavlova, Xenia N. ; Möhlenkamp, Stefan ; Schmermund, Axel ; Seibel, Rainer ; Berenbein, Sina ; Lehmann, Nils ; Moebus, Susanne ; Jöckel, Karl Heinz ; Orekhov, Alexander N. ; Erbel, Raimund. / Blood serum atherogenicity and coronary artery calcification. In: Current Pharmaceutical Design. 2014 ; Vol. 20, No. 37. pp. 5884-5888.
@article{77514ec289e442b899a39184f54f662d,
title = "Blood serum atherogenicity and coronary artery calcification",
abstract = "The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-media thickness progression. The present study was undertaken to test the hypothesis that blood serum atherogenicity and its changes in dynamics may be associated with accumulation of coronary calcium in subclinical atherosclerosis. It was performed in 782 CHD-free participants of The Heinz Nixdorf RECALL (Risk Factors, Evaluation of Coronary Calcium and Lifestyle) Study, in whom blood samples have been taken at the baseline and at the end of 5-year follow-up. Opposite to the previous findings, the changes in serum atherogenicity did not correlate neither with the extent of coronary artery calcification, nor with the changes in Agatston CAC score. There was a moderate but significant rise in serum atherogenicity after 5-year followup period, and the same dynamics was observed for Agatston CAC score, but not for convenient lipid-related risk factors. The absence of association of the changes in serum atherogenicity with the changes in Agatston CAC score, along with previous findings, provides a point of view that serum-induced intracellular cholesterol accumulation is not related to the processes of calcium deposition in arterial wall, since the last one reflects the progression of already existing subclinical atherosclerotic lesions.",
keywords = "Biomarkers, Coronary artery calcification, Intracellular cholesterol accumulation, Lipids, Serum atherogenicity, Subclinical atherosclerosis",
author = "Sobenin, {Igor A.} and Myasoedova, {Veronica A.} and Anisimova, {Elena V.} and Pavlova, {Xenia N.} and Stefan M{\"o}hlenkamp and Axel Schmermund and Rainer Seibel and Sina Berenbein and Nils Lehmann and Susanne Moebus and J{\"o}ckel, {Karl Heinz} and Orekhov, {Alexander N.} and Raimund Erbel",
year = "2014",
month = "3",
day = "1",
language = "English",
volume = "20",
pages = "5884--5888",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "37",

}

TY - JOUR

T1 - Blood serum atherogenicity and coronary artery calcification

AU - Sobenin, Igor A.

AU - Myasoedova, Veronica A.

AU - Anisimova, Elena V.

AU - Pavlova, Xenia N.

AU - Möhlenkamp, Stefan

AU - Schmermund, Axel

AU - Seibel, Rainer

AU - Berenbein, Sina

AU - Lehmann, Nils

AU - Moebus, Susanne

AU - Jöckel, Karl Heinz

AU - Orekhov, Alexander N.

AU - Erbel, Raimund

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-media thickness progression. The present study was undertaken to test the hypothesis that blood serum atherogenicity and its changes in dynamics may be associated with accumulation of coronary calcium in subclinical atherosclerosis. It was performed in 782 CHD-free participants of The Heinz Nixdorf RECALL (Risk Factors, Evaluation of Coronary Calcium and Lifestyle) Study, in whom blood samples have been taken at the baseline and at the end of 5-year follow-up. Opposite to the previous findings, the changes in serum atherogenicity did not correlate neither with the extent of coronary artery calcification, nor with the changes in Agatston CAC score. There was a moderate but significant rise in serum atherogenicity after 5-year followup period, and the same dynamics was observed for Agatston CAC score, but not for convenient lipid-related risk factors. The absence of association of the changes in serum atherogenicity with the changes in Agatston CAC score, along with previous findings, provides a point of view that serum-induced intracellular cholesterol accumulation is not related to the processes of calcium deposition in arterial wall, since the last one reflects the progression of already existing subclinical atherosclerotic lesions.

AB - The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-media thickness progression. The present study was undertaken to test the hypothesis that blood serum atherogenicity and its changes in dynamics may be associated with accumulation of coronary calcium in subclinical atherosclerosis. It was performed in 782 CHD-free participants of The Heinz Nixdorf RECALL (Risk Factors, Evaluation of Coronary Calcium and Lifestyle) Study, in whom blood samples have been taken at the baseline and at the end of 5-year follow-up. Opposite to the previous findings, the changes in serum atherogenicity did not correlate neither with the extent of coronary artery calcification, nor with the changes in Agatston CAC score. There was a moderate but significant rise in serum atherogenicity after 5-year followup period, and the same dynamics was observed for Agatston CAC score, but not for convenient lipid-related risk factors. The absence of association of the changes in serum atherogenicity with the changes in Agatston CAC score, along with previous findings, provides a point of view that serum-induced intracellular cholesterol accumulation is not related to the processes of calcium deposition in arterial wall, since the last one reflects the progression of already existing subclinical atherosclerotic lesions.

KW - Biomarkers

KW - Coronary artery calcification

KW - Intracellular cholesterol accumulation

KW - Lipids

KW - Serum atherogenicity

KW - Subclinical atherosclerosis

UR - http://www.scopus.com/inward/record.url?scp=84911488209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911488209&partnerID=8YFLogxK

M3 - Article

C2 - 24533940

AN - SCOPUS:84911488209

VL - 20

SP - 5884

EP - 5888

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 37

ER -